PureTech Health Plc Денежные средства на акцию
Что обозначает Денежные средства на акцию в PureTech Health Plc?
Денежные средства на акцию PureTech Health Plc является 48.23
Какое определение для Денежные средства на акцию?
Денежные средства на акцию - это наличные денежные средства компании, поделенные на акции компании в обращении.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Денежные средства на акцию компаний в Health Care сектор на LSE по сравнению с PureTech Health Plc
Что делает PureTech Health Plc?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Компании с денежные средства на акцию похож на PureTech Health Plc
- CRISIL имеет Денежные средства на акцию из 47.97
- Agarwal Industrial имеет Денежные средства на акцию из 48.05
- CRISIL имеет Денежные средства на акцию из 48.07
- Chipotle Mexican Grill имеет Денежные средства на акцию из 48.08
- Kaya имеет Денежные средства на акцию из 48.08
- Credicorp имеет Денежные средства на акцию из 48.09
- PureTech Health Plc имеет Денежные средства на акцию из 48.23
- Tata Chemicals имеет Денежные средства на акцию из 48.27
- Aurobindo Pharma имеет Денежные средства на акцию из 48.28
- IZMO имеет Денежные средства на акцию из 48.41
- Vardhman Textiles имеет Денежные средства на акцию из 48.42
- Emmi AG имеет Денежные средства на акцию из 48.43
- NetEase имеет Денежные средства на акцию из 48.50